NGeneBio (354200) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, NGeneBio (354200) reported revenue of 21.2 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202521.2 billion KRW-8.3 billion KRW-6.8 billion KRW[source]
20245.7 billion KRW-16.1 billion KRW-13.9 billion KRW[source]
20234.4 billion KRW-13.4 billion KRW-12.9 billion KRW[source]
202211.0 billion KRW-8.6 billion KRW-9.8 billion KRW[source]
20217.2 billion KRW-8.7 billion KRW-8.4 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202558.5 billion KRW35.0 billion KRW23.5 billion KRW[source]
202434.6 billion KRW12.6 billion KRW22.0 billion KRW[source]
202342.8 billion KRW26.0 billion KRW16.7 billion KRW[source]
202256.2 billion KRW30.7 billion KRW25.5 billion KRW[source]
202143.9 billion KRW9.9 billion KRW34.0 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice